Business Wire

CA-CEQUENCE-SECURITY

10.9.2019 06:02:08 CEST | Business Wire | Press release

Share
Cequence Security Opens EMEA Headquarters and Names Key Execs to Accelerate Protection of Hyper-Connected Enterprises Across EMEA

Cequence Security, a provider of innovative application security solutions for today’s hyper-connected enterprises, today advanced its global expansion with the opening of its EMEA headquarters in Munich, Germany, and the appointments of accomplished cybersecurity executives David Curran as Vice President, EMEA, and James Sherlow as Director of Solutions Engineering. The Cequence Application Security Platform (ASP), which consolidates multiple security functions and breakthrough innovations to protect web, mobile, and API-based applications, will be showcased at three important events:

  • OWASP Global AppSec Conference in Amsterdam, September 26-27, 2019, where Cequence Chief Product Officer and Co-Founder Ameya Talwalkar will be featured as a speaker.
  • ISMG Cybersecurity Summit in London, October 22, 2019, where Ameya Talwalkar will also be featured as a speaker.
  • Aviation ISAC Summit in Barcelona, Spain, the global event for aviation cybersecurity, October 30-November 1, 2019, where Cequence Chief Technology Officer and Co-Founder Shreyans Mehta will be featured as a speaker.

The award-winning Cequence platform, designed to support today’s cloud-native, container-based applications, was most recently chosen over numerous contenders as “Startup of the Year” in security software by Network Products Guide. The company and platform have amassed seven recognitions and awards from peers, customers, and analysts since the platform’s launch in November 2018.

Global leaders in the retail, financial, consumer services, and social media sectors rely on Cequence ASP and its integrated modules to protect their web, mobile, and API-based application tier with unprecedented effectiveness. The CQ botDefense Module thwarts malicious bot attacks by using the patented CQAI analytics engine to detect and defend against automated attacks that appear to be legitimate. The CQ appFirewall module similarly employs CQAI to provide non-stop security, even with continuous application updates and modifications to production apps at scale by DevOps teams. It prevents attacks targeting web, mobile, and API-based applications, and helps eliminate unwanted application traffic on enterprise networks.

“Hyperconnected organizations across the EMEA region are leading today’s digital economy, and their Internet-facing applications and APIs are increasingly the targets of advanced semantic and syntactic attacks,” said David Curran, Cequence Vice President, EMEA. “Cequence ASP provides unprecedented protection against business logic abuse such as Account Takeover, Fake Accounts, Content Scraping, Denial of Inventory, Application-level DDoS, API Abuse, Gift Card Fraud, Click Fraud, and Aggregator Abuse. It’s game-changing technology and I’m honored by the opportunity to help strengthen the security posture of these organizations.”

Additional Resources:
David Curran, Vice President, EMEA – bio
James Sherlow, Director of Solutions Engineering, EMEA – bio
Cequence Security

About Cequence Security

Cequence Security is a venture-backed cybersecurity software company founded in 2015 and based in Sunnyvale, CA. Its mission is to transform application security by consolidating multiple innovative security functions within an open, AI-powered software platform that protects customers web, mobile, and API-based applications – and supports today’s cloud-native, container-based application architectures. The company is led by industry veterans that previously held leadership positions at Palo Alto Networks and Symantec. Customers include F500 organizations across multiple vertical markets, and the solution has earned multiple industry accolades, including 2018 Gartner Cool Vendor. Learn more at www.cequence.ai .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye